|
|
Serge Adnot
J Clin Invest. 2005;
115(6):1461
doi:10.1172/JCI25399
Abstract |
Full text
| PDF
H
yperplasia of pulmonary artery SMCs (PASMCs) is a pathological hallmark of pulmonary arterial hypertension (PAH). In this issue of the JCI, McMurtry et al. report that adenovirus-mediated overexpression of survivin — a multipotent inhibitor of apoptosis — induces PAH in rats, whereas inhalation of an adenovirus vector encoding a mutant survivin gene with dominant-negative properties reverses established monocrotaline-induced PAH. These findings raise important issues regarding the role of survivin in the pathogenesis of PAH, its value as a prognostic indicator, and its use as a target for new therapeutic strategies.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(12)
| Title and authors |
Publication |
Year |
Pulmonary arterial hypertension associated with systemic sclerosis
Stephen C Mathai, Paul M Hassoun
|
Expert Review of Respiratory Medicine
|
2011 |
Comprehensive Physiology
Tamara Tajsic, Nicholas W. Morrell
|
Comprehensive Physiology
|
2010 |
Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension
Jing Huang, John H. Wolk, Michael H. Gewitz, Rajamma Mathew
|
Exp Lung Res
|
2010 |
A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension
M Gomberg-Maitland, M L Maitland, R J Barst, L Sugeng, S Coslet, T J Perrino, L Bond, M E LaCouture, S L Archer, M J Ratain
|
Clin Pharmacol Ther
|
2009 |
Cellular and molecular basis of pulmonary arterial hypertension.
Nicholas W Morrell, Serge Adnot, Stephen L Archer, Jocelyn Dupuis, Peter Lloyd Jones, Margaret R MacLean, Ivan F McMurtry, Kurt R Stenmark, Patricia A Thistlethwaite, Norbert Weissmann, Jason X-J Yuan, E Kenneth Weir
|
Journal of the American College of Cardiology
|
2009 |
Therapies for scleroderma-related pulmonary arterial hypertension.
Paul M Hassoun
|
Expert Review of Respiratory Medicine
|
2009 |
Therapy for pulmonary arterial hypertension associated with systemic sclerosis.
Stephen C Mathai, Paul M Hassoun
|
Current Opinion in Rheumatology
|
2009 |
Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
Paul M. Hassoun, Luc Mouthon, Joan A. Barberà, Saadia Eddahibi, Sonia C. Flores, Friedrich Grimminger, Peter Lloyd Jones, Michael L. Maitland, Evangelos D. Michelakis, Nicholas W. Morrell, John H. Newman, Marlene Rabinovitch, Ralph Schermuly, Kurt R. Stenmark, Norbert F. Voelkel, Jason X.-J. Yuan, Marc Humbert
|
Journal of the American College of Cardiology
|
2009 |
Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension
Marc Humbert, David Montani, Frédéric Perros, Peter Dorfmüller, Serge Adnot, Saadia Eddahibi
|
Vascular Pharmacology
|
2008 |
Combination Therapy and New Types of Agents for Pulmonary Arterial Hypertension
Dermot O'Callaghan, Sean P. Gaine
|
Clinics in Chest Medicine
|
2007 |
|